Schizophrenia Research
Volume 28, Issue 2 , Pages 257-265 , 19 December 1997

Altered consciousness states and endogenous psychoses: a common molecular pathway?

Received 27 March 1997 ,Accepted 11 July 1997.

References 

  1. Angrist B, Gershon S, Sathananthan G. Dimethyltryptamine levels in blood of schizophrenic patients and control subjects. Psychopharmacology. 1976;47:29–32
  2. Beasley ChM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14(2):111–123
  3. Buscaíno GA, Spadetta V, Carella A. Possible applicazione del test di metilazione in vitro della nicotinamide alla diagnosi biochimica della schizophrenia. Acta Neurol. 1966;21(1):1–5
  4. Buscaíno GA, Spadetta V, Carella A. II test de la metilazione nella schizophrenia. Considerazione su una casuística de 500 sperimentazioni. Acta Neurol. 1969;24(2):113–118
  5. 1995 Carlsson A. The dopamine theory revisited. In: Hirsch S, Weinberger DR editor. Schizophrenia. Madrid: Blackwell Science; 1995;p. 379–400
  6. Carpenter WT, Fink EB, Narasimhachari N, Himwich HE. A test of the transmethylation hypothesis in acute schizophrenic patients. Am. J. Psychiatry. 1975;132(10):1067–1071
  7. Checkley SA, Murray RM, Oon MCH, Rodnight R, Birley JLT. A longitudinal study of urinary excretion of N,N-dimethyltryptamine in psychotic patients. Br. J. Psychiatry. 1980;137:236–239
  8. Ciprian-Ollivier J, Cetkovich-Bakmas MG, Boullosa O. Abnormally methylated compounds in mental illness. In: Shagass C, et al. editor. Biological Psychiatry. Oxford, UK: Elsevier Science; 1986;p. 243–245
  9. Ciprian-Ollivier J, Cetkovich-Bakmas MG, Boullosa O, Lopez-Mato A. Psicosis Esquizofrénicas. In: Ciprian-Ollivier J editors. Teoria de la Transmetilación Patológica. Psiquiatría Biológica. Fundamentos y Aplicación Clinica. New York: Científica Interamericana; 1988;p. 75–87
  10. Ciprian-Ollivier J. Delusional status and abnormally methylated compounds. In: Racagni G, Brunello N, Fukuda T editor. Biological Psychiatry. Proceedings of the 5th World Congress of Biological Psychiatry. 9–14 June 1991, Florence, Italy. Buenos Aires: Excerpta Médica; 1991;p. 627–629
  11. Corbett L, Christian ST, Morin RD, Benington F, Smythies JR. Hallucinogenic N-methylated indolealkylamines in the cerebrospinal fluid of psychiatric and control populations. Br. J. Psychiatry. 1978;132:139–144
  12. Fischer E. Biogenic amines in schizophrenia. In: Hawkins D, Pauling L editor. Orthomolecular Psychiatry: Treatment of Schizophrenia. Amsterdam: W.H. Freeman; 1970;p. 179–201
  13. Fischer E, Spatz H, Fledel T. Bufotenin-like substances in form of glucuronide in schizophrenic and normal urines. Psychosomatics. 1971;12:278–280
  14. Fischman LG. Dreams, hallucinogenic drug states, and schizophrenia: a psychological and biological comparison. Schizophr. Bull. 1983;9(1):73–94
  15. December Friedhoff AJ, Van Winkle E. Biological O-Methylation and Schizophrenia. In: Psychiatric Research Report. 19:San Francisco: American Psychiatric Association; 1964;p. 149–153
  16. Gillin JC, Kaplan J, Stillman R, Wyatt RJ. The psychedelic model of schizophrenia: the case of N,N-dimethyltryptamine. Am. J. Psychiatry. 1976;133(2):203–208
  17. Glennon RA, Dukat M. Serotonin receptor subtypes. In: Bloom FE, Kupfer DJ editor. Psychopharmacology: The Fourth Generation of Progress. Washington, DC: Raven Press; 1995;p. 415–429
  18. Heym J, Jacobs BL. Serotonergic Mechanisms of Hallucinogenic Drug Effects. In: Monographs in Neural Science. Vol 13:New York: Karger; 1987;p. 55–81
  19. Hryhorczuk LM, Rainey JM, Frohman ChE, Novak EA. A new metabolic pathway for N,N-dimethyltryptamine. Biol. Psychiatry. 1986;21:84–93
  20. Huber G, Gross G. The concept of basic symptoms in schizophrenic and schizoaffective psychoses. Recent Prog. Med. 1989;80(12):646–652
  21. Jackson DM, Nohell N, Bengtsson A, Malmberg A. What are atypical neuroleptics and how do they work?. In: Brunello N, Mendlewicz J, Racagni G editor. New Generation of Antipsychotic Drugs: Novel Mechanisms of Action. Basel, Switzerland: Karger; 1993;p. 27–38
  22. Kahn RS, Davis KL. New developments in dopamine and schizophrenia. In: Bloom FE, Kupfer DJX editor. Psychopharmacology: The Fourth Generation of Progress. Basel, Switzerland: Raven Press; 1995;p. 1193–1203
  23. Kärkäinen J, Räisäinen M, Naukkarinen H, Spoov J, Rimon R. Urinary excretion of free bufotenin in psychiatric patients. Biol. Psychiatry. 1988;24:441–446
  24. Kärkäinen J, Räisäinen M. Nialamide, an MAO inhibitor, increases urinary excretion of endogenously produced bufotenin in man. Biol. Psychiatry. 1992;32:1042–1048
  25. Kay S. Positive and Negative Syndromes in Schizophrenia. New York: Brunner/Mazel; 1991;
  26. Kelm H. The Hoffer-Osmond Diagnostic Test. In: Hawkins D, Pauling L editor. Orthomolecular Psychiatry: Treatment of Schizophrenia. New York: W.H. Freeman; 1970;p. 327–341
  27. Keup W. Structure-activity relationship among hallucinogenic drugs. In: Keup W editors. Origins and Mechanisms of Hallucinations. San Francisco: Plenum Press; 1970;p. 345–376
  28. Kleinman JE, Gillin JC, Wyatt RJ. A comparison of the phenomenology of hallucinogens and schizophrenia from some autobiographical accounts. Schizophr. Bull. 1977;3(4):560–586
  29. Luchins D, Ban TA, Lehmann HE. A review of nicotinic acid, N-methylated indoleamines and schizophrenia. Int. Pharmacopsychiatry. 1978;13:16–33
  30. McKenna D, Towers GHN, Abbott F. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and β-carboline constituents of ayahuasca. J. Ethnopharmacol. 1984;10:195–223
  31. Murray RM, Oon MC, Rodnight R, Birley JL, Smith A. Increased excretion of dimethyltryptamine and certain features of psychosis: a possible association. Arch. Gen. Psychiatry. 1979;36(6):644–649
  32. O'Donnell B, Swearer JM, Smith LT, Nestor PG, Shenton ME, McCarley RW. Selective deficits in visual perception and recognition in schizophrenia. Am. J. Psychiatry. 1996;153:687–692
  33. Osmond H, Smythies J. Schizophrenia: a new approach. J. Ment. Sci. 1952;98:309–315
  34. Paik IH, Lee Ch, Kim ChE. Platelet MAO in schizophrenics: relationship to symptomatology and neuroleptics. Biol. Psychiatry. 1988;23:93–95
  35. Pinkley HP. Plant admixtures to ayahuasca, the South American hallucinogenic drink. Econ. Botany. 1969;32(3):305–314
  36. in press Pomilio AB, Vitale AA, Ciprian-Ollivier J, Cetkovichbakmas M, Gómez R, Vázquez G. Ayahoasca: an experimental psychosis that mirrors the transmethylation hypothesis of schizophrenia. J. Ethnopharmacol. 1997;
  37. Räisäinen M, Kärkäinen J. Mass fragmentographic quantification of urinary N,N-dimethyltryptamine and bufotenine. J. Chromatogr. 1979;162:579–584
  38. Rodnight R, Murray RM, Oon MCH, Brockington IF, Nicholls P, Birley JLT. Urinary dimethyltryptamine and psychiatric symptomatology and classification. Psychol. Med. 1976;6:649–657
  39. Saavedra JM, Axelrod J. Psychotomimetic N-methylated tryptamines: formation in brain in vivo and in vitro. Science. 1972;172:1365–1366
  40. Sitaram BR, McLeod WR. Observations on the metabolism of the psychotomimetic indolealkylamines: implications for future clinical studies. Biol. Psychiatry. 1990;28:841–848
  41. Smythies JR. Biochemistry and the schizophrenias. South Med J. 1979;72:1272–1276
  42. [editorial] Smythies JR. The transmethylation and one-carbon cycle hypothesis of schizophrenia. Psychol. Med. 1983;13:711–714
  43. Spatz H. Determinación Cuantitativa de la Bufotenina en la Orina de Normales y Enferemos Mentales. Prensa Med. Argentina. 1967;54:216
  44. Stam FC, Heslinga FJM, Van Tilburg W. Schizophrenia and pink spot. Psychiatria Neurol. Neurochirurgia. 1969;72:513–524
  45. Strassman RJ, Qualls CR. Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic and cardiovascular effects. Arch. Gen. Psychiatry. 1994;51:85–97
  46. Strassman RJ, Qualls CR, Uhlenhuth E, Kellner R. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch. Gen. Psychiatry. 1994;51:98–108
  47. Tanimukai H, Ginther R, Spaide J, Bueno JR, Himwich HE. Detection of psychomimetic N,N-dimethylated indoleamines in the urine of four schizophrenic patients. Br. J. Psychiatry. 1970;117:421–430
  48. Vitale AA, Calviño MA, Ferrari CC, Pomilio AB, Ciprian-Ollivier J, Cetkovich-Bakmas MG. Método rápido y sensible para detectar aminas primarias y secundarias no fenólicas en orina humana Acta Bioquim. Clin. Latinoam. 1994;28(4):1–10
  49. Wolbach AB, Miner EJ, Isbell H. Comparison of psilocin with psilocybin, mescaline and LSD25. Psychopharmacologia. 1962;3:219–223
  50. Wyatt RJ, Gillin JJ. The transmethylation hypothesis: a quarter of a century later. Psychiatr. Ann. 1976;6(1):35–49
  51. Zureick J, Meltzer HY. Platelet MAO activity in hallucinating and paranoid schizophrenics: a review and metaanalysis. Biol. Psychiatry. 1988;24:63–78

PII: S0920-9964(97)00116-3

doi: 10.1016/S0920-9964(97)00116-3

Schizophrenia Research
Volume 28, Issue 2 , Pages 257-265 , 19 December 1997

Article Tools